Mode
Text Size
Log in / Sign up

Allergy & Immunology

604 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Depemokimab maintains trough concentrations 90% above EC level with predicted half-life of 47 days
Allergy & Immunology RCT
Depemokimab maintains trough concentrations 90% above EC level with predicted half-life of 47 days New data supports twice yearly dosing for asthma and sinus disease
This observational analysis of pharmacokinetic and pharmacodynamic data from Phase I and Phase III trials evaluated depemokimab in patients …
A new analysis of trial data shows a specific treatment for asthma and nasal polyps may only need to be given twice a year.
High-dose omega-3 PUFA and EPA significantly reduce risk of asthma and wheezing in children
Allergy & Immunology Meta-analysis
High-dose omega-3 PUFA and EPA significantly reduce risk of asthma and wheezing in children High dose omega-3 fatty acids may lower asthma risk in children
This meta-analysis of 4156 children evaluated the impact of omega-3 polyunsaturated fatty acids on asthma. Findings indicate that high-dose …
New data suggests that specific high doses of omega-3 fatty acids and EPA could significantly reduce the risk of asthma and wheezing in chil…
Cloud-based intelligent management system improves medication adherence 89.2% vs 58.0% in pediatric asthma
Allergy & Immunology RCT
Cloud-based intelligent management system improves medication adherence 89.2% vs 58.0% in pediatric asthma Smart monitoring helps children with asthma manage their symptoms better
This randomized controlled trial of 208 children aged 6 to 12 years found that a cloud-based integrated intelligent management system signif…
A cloud-based management system significantly improved medication habits and lung function for children living with bronchial asthma.
Nanomedicine platforms reshape osteosarcoma tumor microenvironment, showing strong preclinical potential
Allergy & Immunology Sys. Review
Nanomedicine platforms reshape osteosarcoma tumor microenvironment, showing strong preclinical potential New delivery methods show promise for treating bone cancer
This mini-review examines nanomedicine delivery systems, including biomimetic, stimuli-responsive, and bone-targeted platforms, for osteosar…
Nanomedicine platforms may help overcome physical and cellular barriers to reshape the environment around osteosarcoma tumors.
Asthma and COPD are associated with significantly increased risk of pertussis infection
Allergy & Immunology Meta-analysis
Asthma and COPD are associated with significantly increased risk of pertussis infection Asthma and COPD Patients Face Higher Risk of Pertussis Infection
This meta-analysis of 10 studies involving over 18.6 million participants indicates that patients with asthma or COPD face a higher risk of …
People with asthma or COPD may face a significantly higher risk of contracting pertussis, according to an analysis of over 18 million partic…
FDA Approves Cellcept (mycophenolate mofetil) for Organ Rejection Prophylaxis
Allergy & Immunology FDA Approval
FDA Approves Cellcept (mycophenolate mofetil) for Organ Rejection Prophylaxis FDA approves Cellcept to prevent organ rejection in transplant patients.
The FDA approved Cellcept (mycophenolate mofetil) for prophylaxis of organ rejection in adult and pediatric recipients 3 months and older of…
The FDA has approved Cellcept (mycophenolate mofetil) to help prevent organ rejection in patients who have received a kidney, heart, or live…
FDA Approves Cellcept (mycophenolate mofetil) for Organ Rejection Prophylaxis
Allergy & Immunology FDA Approval
FDA Approves Cellcept (mycophenolate mofetil) for Organ Rejection Prophylaxis FDA approves Cellcept to prevent organ rejection in transplant patients.
The FDA approved Cellcept (mycophenolate mofetil) for prophylaxis of organ rejection in adult and pediatric patients 3 months and older rece…
The FDA has approved Cellcept (mycophenolate mofetil) to help prevent organ rejection in adults and children aged 3 months and older who hav…
FDA Approves Myhibbin (mycophenolate mofetil) for Organ Rejection Prophylaxis
Allergy & Immunology FDA Approval
FDA Approves Myhibbin (mycophenolate mofetil) for Organ Rejection Prophylaxis FDA approves new liquid and capsule form of transplant rejection drug
The FDA approved Myhibbin (mycophenolate mofetil) for prophylaxis of organ rejection in adult and pediatric recipients 3 months and older of…
The FDA approved Myhibbin, a new form of mycophenolate mofetil, to prevent organ rejection in kidney, heart, and liver transplant patients a…
Chemo combinations with ivonescimab, sacituzumab tirumotecan, and amivantamab show significant progression-free survival benefits
Allergy & Immunology Meta-analysis
Chemo combinations with ivonescimab, sacituzumab tirumotecan, and amivantamab show significant progression-free survival benefits New Treatment Combinations Show Promise for Advanced Lung Cancer
This systematic review and meta-analysis of 3,606 patients evaluated 8 treatment strategies for advanced EGFR-mutant NSCLC. The analysis fou…
Specific drug combinations, including ivonescimab and amivantamab, show potential benefits for patients with advanced EGFR-mutant lung cance…
Triple consolidation with CAR T cells yields sustained remission in relapsed BPDCN
Allergy & Immunology Sys. Review
Triple consolidation with CAR T cells yields sustained remission in relapsed BPDCN New treatment strategy shows promise for rare blood cancer
This case report and literature review describes a 55-year-old man with relapsed/refractory BPDCN and CNS involvement who achieved sustained…
A new three-part treatment plan helped a man with a rare, aggressive blood cancer achieve long-term remission when no donor was available.
Bortezomib, cyclophosphamide, and dexamethasone achieved remission in a patient with AL amyloidosis and POEMS syndrome
Allergy & Immunology Sys. Review
Bortezomib, cyclophosphamide, and dexamethasone achieved remission in a patient with AL amyloidosis and POEMS syndrome Treatment shows success for heart failure and rare blood diseases
This case report and literature review describes the treatment of an elderly male with concurrent AL amyloidosis and POEMS syndrome. The pat…
A new look at a complex case reveals how a specific drug combination helped an elderly man with multiple rare conditions.
Combination Immunotherapy Improves Outcomes for BCG Unresponsive Non Muscle Invasive Bladder Cancer
Allergy & Immunology RCT
Combination Immunotherapy Improves Outcomes for BCG Unresponsive Non Muscle Invasive Bladder Cancer Combination immunotherapy shows promise for bladder cancer patients
Multi-agent immunotherapy regimens show superior response rates and progression-free survival compared to monotherapy in patients with NMIBC…
A new combination of immunotherapies may improve response rates and survival for patients with specific types of bladder cancer.

All Allergy & Immunology Articles